These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29451226)

  • 1. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT; Yassin MA; De Sanctis V
    Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA; Soliman AT; De Sanctis V; Abdula MAJ; Riaz LM; Ghori FF; Yousaf A; Nashwan AJ; Abusamaan S; Moustafa A; Kohla S; Soliman DS
    Acta Biomed; 2018 Feb; 89(2-S):33-40. PubMed ID: 29451227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.
    Yassin MA; Soliman AT; De Sanctis V; Yassin KS; Abdulla MA
    Mediterr J Hematol Infect Dis; 2019; 11(1):e2019026. PubMed ID: 31205630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
    Kanbour I; Chandra P; Soliman A; De Sanctis V; Nashwan A; Abusamaan S; Moustafa A; Yassin MA
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018062. PubMed ID: 30416694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
    Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
    Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone deficiency (GHD) in adult thalassaemic patients.
    Scacchi M; Danesi L; Cattaneo A; Valassi E; Pecori Giraldi F; Argento C; D'Angelo E; Mirra N; Carnelli V; Zanaboni L; Cappellini MD; Cavagnini F
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):790-5. PubMed ID: 17608814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V
    Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age related IGF-I changes and IGF-I generation in thalassemia major.
    Soliman AT; Abushahin A; Abohezeima K; Khalafallah H; Adel A; Elawwa A; Elmulla N
    Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():278-83. PubMed ID: 21705978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone - insulin-like growth factor-I axis and bone mineral density in adults with thalassemia major.
    Soliman A; De Sanctis V; Yassin M; Abdelrahman MO
    Indian J Endocrinol Metab; 2014 Jan; 18(1):32-8. PubMed ID: 24701427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data.
    Soliman AT; El Banna N; Abdel Fattah M; ElZalabani MM; Ansari BM
    Metabolism; 1998 May; 47(5):541-8. PubMed ID: 9591744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
    Grumbach MM; Bin-Abbas BS; Kaplan SL
    Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth deficiency in polytransfused beta-thalassaemia patients is not growth hormone dependent.
    Cavallo L; Gurrado R; Gallo F; Zacchino C; De Mattia D; Tatò L
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):701-6. PubMed ID: 9274700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.
    Soliman AT; El Banna N; Ansari BM
    Eur J Endocrinol; 1998 Apr; 138(4):394-400. PubMed ID: 9578506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.
    Moayeri H; Oloomi Z
    Arch Iran Med; 2006 Oct; 9(4):329-34. PubMed ID: 17061604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.